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Production of 8-Halogenated and 8-Unsubstituted
Novobiocin Derivatives in Genetically Engineered
Streptomyces coelicolor Strains
Natural products play a dominant role in the discovery
of drugs for infectious diseases [3]. Structural modifica-
tions of these natural products are often necessary for
improvements in efficacy and pharmacokinetics. Yet,
introduction of structural changes by chemical synthe-
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Auf der Morgenstelle 8 namely, the shuffling of genes with related functions but
different specificities via genetic engineering to create72076 Tu¨bingen
Germany combinatorial libraries of novel natural product-like mol-
ecules [4], offers a recently developed alternative way2 Department of Molecular Microbiology
John Innes Centre to introduce structural modifications. In addition, ratio-
nal and directed generation of structurally modified anti-Norwich Research Park
Colney, Norwich NR4 7UH biotics can be achieved by metabolic engineering of
biosynthetic pathways, i.e., by the modification of spe-United Kingdom
3 Fakulta¨t fu¨r Biologie cific biochemical reactions or the introduction of new
ones by using recombinant DNA technology [5], as dem-Mikrobiologisches Institut
Mikrobiologie/Biotechnologie onstrated, e.g., by Yanai et al. [6].
Clorobiocin (chlorobiocin) and novobiocin (Figure 1)Eberhard-Karls-Universita¨t Tu¨bingen
Auf der Morgenstelle 28 belong to the class of aminocoumarin antibiotics, which
are highly suitable for drug development by metabolic72076 Tu¨bingen
Germany engineering. They are potent inhibitors of bacterial DNA
gyrase and are produced by different Streptomyces
strains [7–9]. The efficacy of novobiocin against gram-
positive bacteria such as methicillin-resistant Staphylo-Summary
coccus aureus (MRSA) and Staphylococcus epidermidis
has been demonstrated in preclinical and clinical trialsIn the present study, we produced a hybrid antibiotic,
carrying a chlorine atom instead of a methyl group at [10–12]. Novobiocin and its derivatives have also been
investigated as potential anticancer drugs [13–15]. Ourposition 8 of the aminocoumarin moiety of novobiocin.
This compound was not accessible by conventional group has recently cloned and sequenced the biosyn-
thetic gene clusters of clorobiocin (clo) and novobiocingene inactivation/gene expression experiments due to
difficulties in the genetic manipulation of the novobio- (nov) [16, 17].
Clorobiocin is the more potent of the two aminocou-cin producer Streptomyces spheroides. However, the
desired compound was obtained after modification of marin antibiotics [18]. It differs from the clinically ap-
proved drug novobiocin in the substitution pattern atthe novobiocin biosynthetic gene cluster by using
-Red-mediated recombination in Escherichia coli, C-8 of the aminocoumarin ring, carrying a chlorine atom
instead of a methyl group, and in the presence of afollowed by integration of the resulting modified cos-
mid into the φC31 attachment site of Streptomyces 5-methylpyrrole-2-carboxyl moiety instead of a carbam-
oyl group at 3″-OH of the deoxysugar unit (Figure 1).coelicolor and coexpression of the halogenase Clo-
hal of clorobiocin biosynthesis. The halogenase BhaA, We aimed at the production of hybrid antibiotics by
combining structural features of these two compounds.responsible for chlorination of tyrosyl moieties of the
glycopeptide antibiotic balhimycin, was unable to A clorobiocin analog with -CH3 instead of -Cl at C-8
(novclobiocin 102; Figure 1) was readily obtained byfunctionally replace the halogenase Clo-hal, sug-
gesting that the two enzymes have different substrate inactivation of the halogenase gene clo-hal in the cloro-
biocin producer Streptomyces roseochromogenes andspecificities.
by subsequent expression of the methyltransferase
gene novO from the novobiocin producer S. spheroidesIntroduction
in the clo-hal mutant [19].
However, when we attempted an inactivation of novOAntibiotic resistance has developed in every class of
in the novobiocin producer S. spheroides, followed byantibiotics, both natural and synthetic, within a few years
expression of the halogenase clo-hal in the novO mu-after the first clinical use [1]. Therefore, there is a con-
tant in order to generate a hybrid antibiotic with a chlo-stant need for the development of new antibacterial
rine atom at C-8 and a carbamoyl group at 3″-OHdrugs in order to reduce the impact of resistance in
(novclobiocin 114; Figure 1), this strategy remainedantibacterial therapy, as emphasized by the World
unsuccessful (F. Pojer and L.H., unpublished data).Health Organization [2].
S. spheroides is very difficult to manipulate genetically
[20], and this may have been the cause for the failure of*Correspondence: heide@uni-tuebingen.de
our experiment. Similar problems encountered in many4 Present address: Combinature Biopharm AG, Robert-Ro¨ssle-Str.
10, 13125 Berlin, Germany. important antibiotic-producing strains severely limit the
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Figure 1. Structures of Aminocoumarins
Structures of the aminocoumarin antibiotics novobiocin and clorobiocin, and of the hybrid antibiotics novclobiocin 102 and 114.
possibilities for combinatorial biosynthesis and meta- (see the Experimental Procedures). The resulting cosmid
nov-BG1 is depicted in Figure 2A. Of the 45 kb insert,bolic engineering.
In the present study, we therefore attempted to cir- the entire novobiocin cluster and parts of the flanking
regions have been sequenced, while approximately 10cumvent the problem of genetic manipulation in
S. spheroides by heterologous expression of the entire kb of insert sequence are yet unknown.
The cosmid nov-BG1 was then introduced into S. coe-biosynthetic gene cluster of novobiocin in S. coelicolor,
which is well characterized and easy to manipulate [21, licolor M512 by PEG-mediated protoplast transforma-
tion. Southern blot analysis confirmed its integration into22]. Indeed, the desired compound, novclobiocin 114,
was readily produced by this method. the genome of S. coelicolor. After hybridization with the
DIG-labeled cosmid nov-BG1, S. coelicolor integrationParallel expression experiments in the heterologous
producer strain, using either clo-hal from the clorobiocin mutants showed all of the bands expected from the
specific integration of nov-BG1 into the φC31 attach-producer or the very similar gene bhaA from the balhi-
mycin producer [23], showed that these two halo- ment site, while the parental strain gave no hybridization
signals (Figure 2D, lanes 1 and 2).genases are not interchangeable, despite their sequence
similarity and their common involvement in a 3-chlorina- Two independent integration mutants as well as the
parental strain were cultured in novobiocin productiontion of a -hydroxy-tyrosine derivative.
medium. The analysis of secondary metabolites by
HPLC showed that the mutants (Figure 3B), in contrast toResults
the parental strain (Figure 3A), accumulated novobiocin.
This compound was isolated on a preparative scale. TheHeterologous Expression of the Intact Novobiocin
Biosynthetic Gene Cluster identity of the produced novobiocin was confirmed by
1H NMR analysis (Table 1; Figure 4). The obtained signalsWe have previously cloned the biosynthetic gene cluster
of novobiocin into the SuperCos I vector, resulting in were identical to those from authentic novobiocin. Neg-
ative-ion FAB MS analysis showed a molecular ioncosmid 10-9C [16]. For the heterologous expression, the
ampicillin resistance gene in the SuperCos I backbone [M-H] at m/z 611 (novobiocin is C31H36N2O11; molecular
weight  612).of cosmid 10-9C was replaced by a cassette containing
the integrase gene (int) and attachment site (attP) of The two S. coelicolor strains that had integrated the
novobiocin biosynthetic gene cluster produced on aver-phage φC31 by using -Red-mediated recombination
Novobiocin Derivatives
1563
Figure 2. Heterologous Expression of the Novobiocin Biosynthetic Gene Cluster in S. coelicolor and Inactivation of novO
(A) Schematic presentation of cosmids nov-BG1, containing the intact novobiocin biosynthetic gene cluster, and nov-AE8, in which novO was
deleted. The novobiocin cluster is presented in gray, the flanking regions are presented in white, and novO is presented in black. B  BglII
restriction site. T3 and T7 indicate the orientation of the cluster in the SuperCos I vector. tet  tetracycline resistance gene; neo  neomycin/
kanamycin resistance gene; int, attP  integrase and attachment site, respectively, of phage φC31. The cosmid backbone is not shown to
scale.
(B) Schematic presentation of site-specific integration. The integrase, int, derived from Streptomyces phage φC31 catalyzes integration via
recombination between attP (from phage or vector) and attB (from Streptomyces genome) sites, generating the hybrid sites attL and attR
[47]. Junction fragments that prove specific integration into the φC31 attachment site of the S. coelicolor genome are indicated. This figure
is not shown to scale.
(C) Schematic presentation of the novO inactivation. novO (693 bp) was first replaced by an apramycin resistance (aac(3)IV) cassette. Afterwards,
the cassette was excised by digestion with XbaI and SpeI and religated, leaving an in-frame “scar” of 18 nucleotides between the start and
stop codons of novO. This figure is not shown to scale.
(D) Southern blot analysis of S. coelicolor M512 (lane 1) and M512-derived integration mutants bearing cosmid nov-BG1 (lane 2) or the novO
cosmid nov-AE8 (lane 3). M  DIG-labeled DNA Molecular Weight Marker VII (Roche). Genomic DNA was digested with BglII. The DIG-labeled
cosmid nov-BG1 was used as a probe. The novO inactivation is confirmed by the 3.1 kb band (lane 3) instead of a 3.8 kb band (lane 2);
otherwise, the band pattern should be identical.
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Figure 3. HPLC Analysis of Secondary Me-
tabolites
(A) S. coelicolor M512 parental strain.
(B) S. coelicolor (nov-BG1), carrying the no-
vobiocin biosynthetic gene cluster.
(C) S. coelicolor (nov-AE8), novO mutant.
(D) S. coelicolor (nov-AE8)/pAE-ha7, novO
mutant transformed with the clo-hal expres-
sion construct (pAE-ha7). Detection at 305
nm. The major products are emphasized by
a larger font size.
age 31 mg novobiocin per liter, comparable to the pro- Therefore, novO was replaced by an apramycin resis-
tance cassette flanked by XbaI and SpeI recognitionductivity of the natural producer S. spheroides (35 mg/l).
sites via -Red-mediated recombination [24]. The cas-
sette was then removed by digestion with XbaI andHeterologous Expression of a Modified
Novobiocin Cluster (novO) SpeI, enzymes that create compatible ends, allowing
religation of the outer ends and consequent excision ofSince heterologous expression of the intact novobiocin
biosynthetic gene cluster was successful, we attempted the cassette (Figure 2C). This procedure leaves a mini-
mal in-frame “scar” of 18 nucleotides inside the targetedto generate a modified (8-unsubstituted) antibiotic by
inactivation of the methyltransferase gene novO in cos- sequence. The modified cosmid (named nov-AE8) was
then introduced into S. coelicolor by transformation.mid nov-BG1 and introduction of this modified cosmid
into the genome of S. coelicolor. Southern blot analysis confirmed the integration into the
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Table 1. 1H NMR Data of Novobiocin, Novclobiocic Acid 106, Novclobiocin 117, Novclobiocin 114, and Novclobiocin 119 in d4-Methanol
Compound
Novclobiocic
Novobiocin Acid 106 Novclobiocin 117 Novclobiocin 114 Novclobiocin 119
, Multiplicity , Multiplicity , Multiplicity , Multiplicity , Multiplicity
Position (J/Hz) (J/Hz) (J/Hz) (J/Hz) (J/Hz)
2-H 7.75 bra s 7.76 br s 7.76 br s 7.75 br s 7.76 br s
5-H 6.84 d (8.3) 6.83 d (8.4) 6.82 d (8.2) 6.84 d (8.3) 6.82 d (8.3)
6-H 7.72 br d (8.3) 7.72 br d (8.4) 7.72 br d (8.2) 7.72 br d (8.3) 7.72 br d (8.3)
7-H2 3.34 d (7.3) 3.34 d (7.5) 3.33b 3.33 d (7.1) 3.33 d (6.9)
8-H 5.34 mt (7)c 5.35 br t (7.5) 5.35 mt (7)d 5.35 mt (7)c 5.35 br t (7)d
10-H3 1.74 s 1.74 br s 1.74 br s 1.74 s 1.74 br s
11-H3 1.75 s 1.74 br s 1.74 br s 1.75 s 1.74 br s
5-H 7.81 d (8.9) 7.81 br d (8.0) 7.91 br d (7.5) 7.88 d (8.9) 7.88 d (8.8)
6-H 7.23 br d (8.9) 6.78 br d (8.3) 7.00 br d (7.6)c 7.29 d (8.9) 7.26 d (9.1)
8-H — 6.68 s 7.00 s — —
11-H3 2.31 s — — — —
1″-H 5.57 br s — 5.55 d (2.3) 5.67 br s 5.74 br s
2″-H 4.23 tb — 4.18 t (2.8) 4.28 tb 5.10 tb
3″-H 5.31 dd (3; 10)c — 5.25 dd (3.1; 9.6) 5.36 dd (2.8; 10.0)c 4.35 dd (3.4; 9.9)
4″-H 3.57 d (9.9) — 3.54 d (10.2) 3.58 d (10.0) 3.40 d (9.9)
6″-H3 1.14 s — 1.17 s 1.15 s 1.14 s
7″-H3 1.34 s — 1.35 s 1.32 s 1.32 s
8″-H3 3.55 s — 3.53 s 3.55 s 3.60 s
The numbering of the structures is shown in Figure 4.
 is given in ppm. The solvent signal (3.30 ppm) was used as reference. Spectra were obtained at 400 MHz.
a br  broad signal.
b J is not determinable.
c Complex, overlapping signals; J is not exactly determinable.
d Complex signal; J is not exactly determinable.
genome, and the deletion of novO was clearly shown by Instead, the novobiocin derivative novclobiocin 117, car-
rying a hydrogen instead of a methyl group at C-8,the shortening of the relevant BglII restriction fragment
accumulated. The structure was confirmed by negative-(Figure 2D, lane 3).
ion FAB MS (molecular ion [M-H] at m/z 597 corre-The analysis of secondary metabolites by HPLC (Fig-
sponding to the loss of a methyl group in comparisonure 3C) showed the complete absence of novobiocin.
to novobiocin) and by 1H NMR analysis (Table 1) of the
isolated compound, which clearly showed the absence
of the signal for 8-CH3. These spectroscopic data are in
accordance with the literature [25, 26]. The novO mutant
also produced a minor product (novclobiocic acid 106)
with shorter retention time than novclobiocin 117. This
compound lacked the entire deoxysugar moiety, as
shown by a molecular ion [M-H] at m/z 380 in MS
analysis and by the absence of sugar protons in 1H NMR
analysis (Table 1). In addition, a third compound was
detected with a slightly higher retention time than nov-
clobiocin 117. This substance showed a molecular ion
[M-H] at m/z 597, i.e., identical to novclobiocin 117. As
explained below, this compound is likely to represent
an isomer of novclobiocin 117, carrying the carbamoyl
moiety in position 2 instead of 3 of the deoxysugar. The
production of such 2″-acylated isomers has previously
been observed in strains of S. roseochromogenes, the
clorobiocin producer [27, 28].
The S. coelicolor strain harboring the novO-defective
cluster produced 30 mg/L novclobiocin 117 and 10 mg/L
novclobiocic acid 106. Its productivity was therefore
similar to that of the S. coelicolor strains carrying the
intact novobiocin biosynthetic gene cluster (see above).
Complementation of the novO Mutation
To prove that only the inactivation of novO was responsi-Figure 4. Chemical Structure of Aminocoumarin Antibiotics Gener-
ated in This Study ble for the loss of the methyl group, we complemented
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the mutant by expressing an intact copy of novO. For Antibacterial Activity of Novclobiocins
in Comparison to Novobiocinthis purpose, we used a derivative of the replicative
vector pUWL201, in which novO was placed under the The obtained novclobiocins (i.e., novclobiocin 114, 119,
117, and novclobiocic acid 106; see Figure 4 for struc-control of the constitutive ermE* promoter (plasmid
pTLO5). After pTLO5 was used to transform the novO tures) were assayed for antibiotic activity against Bacil-
lus subtilis in comparison to authentic novobiocin (Fig-mutant, HPLC analysis showed that the novobiocin pro-
duction was restored to about 80% of the productivity ure 5). In accordance with results obtained previously
[19, 26, 30], substitution at C-8 with either -CH3 or -Clobserved before novO inactivation (data not shown).
The identity of novobiocin was confirmed by negative- was important for biological activity: novclobiocin 117
(8-H) showed only 4% of the activity of novobiocin,ion FAB MS analysis (molecular ion [M-H] at m/z 611).
while novclobiocin 114 (8-Cl) was half as active as
novobiocin (8-CH3). Further investigations of the struc-Expression of the Halogenase clo-hal
in the novO Mutant ture-activity relationships of these compounds are in
progress.In order to obtain the desired novobiocin analog carrying
a chlorine atom instead of a methyl group at C-8, the As reported for clorobiocin derivatives [30], the trans-
fer of the acyl group from 3″-OH to 2″-OH resulted in ahalogenase gene clo-hal from the clorobiocin biosyn-
thetic gene cluster was expressed in the S. coelicolor reduction but not in a complete loss of activity: novclobi-
ocin 119 still showed approximately 20% of the activitystrain harboring the novO-defective cluster by using the
replicative plasmid pAE-ha7 in which clo-hal was under of novclobiocin 114. In contrast, the removal of the de-
oxysugar moiety and the 8-substituent (novclobiocicthe control of the constitutive ermE* promoter [19]. As
shown by HPLC (Figure 3D), the resulting clo-hal trans- acid 106) resulted in a 99% loss of activity.
formants produced a substance that was absent from
transformants carrying the empty replicative vector
Expression of the Halogenase bhaApUWL201 (data not shown). Negative-ion FAB MS of the
in the novO Mutantisolated compound showed a molecular ion [M-H] at
The glycopeptide antibiotic balhimycin (Figure 6) andm/z 631, corresponding to the substitution of a hydrogen
the aminocoumarin antibiotic clorobiocin both containby a chlorine atom in the molecule of novclobiocin 117.
3-chloro--hydroxy-tyrosyl-derived moieties. In bothThe typical isotopic pattern caused by the chlorine iso-
compounds, the biosynthesis of these moieties startstopes 35Cl and 37Cl was clearly visible (mass [intensity]:
from L-tyrosine, which forms a thioester bond with an631 [100.0%], 632 [30.6%], 633 [31.9%], 634 [11.2%]).
activating enzyme, i.e., BpsD or CloH, respectively. Sub-1H NMR analysis (Table 1) unequivocally confirmed that
sequently, the cytochrome P450 enzymes OxyD or CloI,the chlorine atom was attached at C-8 of the aminocou-
respectively, introduce the -hydroxy group (Figure 6)marin core: the signal at 7.00 ppm corresponding to the
[31, 32]. The predicted protein sequences of CloH andtwo protons, H-6 and H-8, of novclobiocin 117 had
CloI show clear sequence similarity to BpsD and OxyD.disappeared, and instead a signal at 7.27 ppm (doublet,
The introduction of the chlorine atom into position 3 of1H) was observed, which could be assigned to H-6. In
the aromatic nucleus of the -hydroxy-tyrosyl moietiescomparison, the H-6 signal of novobiocin was seen
is catalyzed by enzymes with sequence similarity toas a doublet (1H) at 7.23 ppm (Table 1). As observed
FADH2-dependent halogenases [33]. The predictedpreviously [19, 26], the chlorine atom at C-8 in clorobio-
amino acid sequence of BhaA of the balhimycin clustercin causes a slightly different magnetic shift of the H-6
[34] shows 36% identity to Clo-Hal of the clorobiocinsignal than a methyl group at the same position. The
cluster [19]. In the biosynthesis of both antibiotics, it isaccumulated substance was therefore unequivocally
unknown which exact intermediate serves as a substrateidentified as novclobiocin 114 (Figure 1). The three inde-
for the halogenation.pendent clo-hal transformants tested produced on aver-
In order to verify whether bhaA could functionally re-age 14 mg novclobiocin 114 per liter of medium. The
place clo-hal, we placed bhaA under the control of theminor peak with slightly longer retention time represents
constitutive ermE* promoter by using the same expres-the isomer of novclobiocin 114, i.e., novclobiocin 119,
sion vector, pUWL201, as employed for the experimentswhich carries the carbamoyl moiety in position 2 instead
with clo-hal described above. The resulting plasmid wasof 3 of the deoxysugar. In the negative-ion FAB MS, it
termed pAE-B3. pAE-B3 was constructed by cloning ashowed the same molecular ion [M-H] at m/z 631 and
BamHI-XbaI fragment of plasmid pSETbhaA, containinga similar isotopic pattern (mass [intensity]: 631 [100.0%],
the bhaA gene and its natural ribosome binding site,632 [34.7%], 633 [32.1%], 634 [12.5%]) as novclobiocin
[34] into the same sites of pUWL201. pSETbhaA has114. Furthermore, in the 1H NMR analysis (Table 1), the
been successfully used for complementation of a bhaAsignal of H-2″ was seen at 5.10 ppm instead of 4.28
mutant of Amycolatopsis balhimycina [34].ppm, and the signal of H-3″ was seen at 4.35 instead
pAE-B3 was introduced by protoplast transformationof 5.36 ppm. Therefore, the chemical shift of the sugar
into the S. coelicolor strain containing the novO-defec-protons demonstrates the presence of the carbamoyl
tive novobiocin cluster. In three independent trans-moiety in position 2 instead of 3, in accordance with
formants, the presence of the intact plasmid was con-published data on novobiocin and isonovobiocin [29].
firmed by plasmid isolation and restriction analysis.The minor peaks with shorter retention times than
However, HPLC analysis of the three transformantsnovclobiocin 114 (Figure 3D) represent the remaining
showed no changes in comparison to the untransformednonhalogenated compounds, i.e., novclobiocin 117 and
novclobiocic acid 106. control, or to controls transformed with the empty vector
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Figure 5. Antibacterial Activity of Novobiocin
and Derivatives
Bioassay against Bacillus subtilis. Activities
are expressed relative to novobiocin (100%).
For structures, see Figure 4.
pUWL201. The detected compounds still showed the Discussion
same molecular ions in the negative-ion FAB MS analy-
sis as those seen in the S. coelicolor strain with the In this study, we have developed a strategy for the pro-
duction of a hybrid antibiotic, novclobiocin 114, whichnovO cluster ([M-H] at m/z 597, corresponding to nov-
clobiocin 117; and [M-H] at m/z 380, corresponding to carries a chlorine atom instead of a methyl group at
position 8 of the aminocoumarin unit of novobiocin.novclobiocic acid 106). Therefore, no chlorinated prod-
ucts could be observed after expression of bhaA in the This compound could not be produced by gene inactiva-
tion and heterologous gene expression experiments innovO mutant.
In order to confirm this result, we also introduced the novobiocin producer Streptomyces spheroides be-
cause of difficulties in the genetic manipulation of thisthe bhaA expression plasmid pAE-B3 into the clo-hal
mutant of the clorobiocin producer S. roseochromo- strain. Yet, through heterologous expression of the en-
tire novobiocin biosynthetic gene cluster in S. coelicolor,genes, constructed in a previous study [19]. Again, bhaA
was unable to complement the mutant. HPLC analysis novobiocin and, after appropriate modification of the
cluster, both the 8-H compound (novclobiocin 117) andof three independent transformants, as well as FAB MS
analysis of the isolated compounds, showed only the the 8-Cl compound (novclobiocin 114) were readily ob-
tained from the resulting strains.same metabolites as detected in the clo-hal mutants
prior to transformation. The dominant product was a Obviously, further novobiocin derivatives may be ob-
tained by modifying other genes of the novobiocin clus-clorobiocin derivative with a hydrogen instead of a chlo-
rine atom at C-8 ([M-H] at m/z 661). If, however, the ter, offering a strategy for the production of a number of
3″-carbomylated aminocoumarin antibiotics, in additionclo-hal mutant was transformed with plasmid pAE-ha7,
which contains clo-hal rather than bhaA and is otherwise to the previously described chemoenzymatic methods
[26, 35].identical to pAE-B3, clorobiocin production was readily
restored. The resulting chromatogram corresponded to Clorobiocin (Figure 1) has been reported to show a
higher inhibition of Escherichia coli gyrase and bacterialthat of the wild-type S. roseochromogenes, and the
identity of clorobiocin was confirmed by negative-ion growth than novobiocin [18] and to bind more tightly to
isolated gyrase [36–38]. The relative contribution of theFAB MS analysis (mass [intensity]: 695 [100.0%, [M-H]],
696 [36.5%], 697 [30.2%], 698 [10.5%]). These experi- 5-methylpyrrole-2-carboxyl moiety at 3″-OH of clorobio-
cin and of the chlorine atom at C-8 to this effect is notments provide clear evidence that clo-hal cannot be
functionally replaced by bhaA. known [19, 38, 39].
Chemistry & Biology
1568
Figure 6. Biosynthesis of the 3-Chloro--Hydroxy-Tyrosyl-Derived Moieties of Clorobiocin and Balhimycin
In both pathways, it is unknown at which exact step during biosynthesis the halogenation takes place (see text). The 3-chloro--hydroxy-
tyrosyl-derived moieties of clorobiocin and balhimycin are emphasized by a larger font size.
The substances produced in this study (novobiocin sis of these moieties shows striking similarities (see
Results section and Figure 6). It is not clear at present atanalogs with -CH3, -H, or -Cl at C-8) and in additional
experiments will allow an investigation of the structure- which step of clorobiocin biosynthesis the halogenation
reaction takes place. In novobiocin biosynthesis, theactivity relationships of such aminocoumarin com-
pounds through the use of both antibacterial assays and methylation at C-8 (corresponding to the chlorination
at C-8 in clorobiocin biosynthesis) occurs only afterin vitro investigations with purified gyrase.
An accumulation of truncated intermediates, lacking activation of tyrosine (Figure 6) [31], and before glycosyl-
ation of novobiocic acid [16]. Possible substrates of Clo-the deoxysugar moiety, was observed in mutants car-
rying modified biosynthetic pathways, i.e., in the novO hal therefore include -hydroxy-tyrosyl-CloH, 3-amino-4,
7-dihydroxycoumarin, and the amide of this aminocouma-mutant (Figure 3C) and in the novO mutant comple-
mented with clo-hal (Figure 3D). This may indicate that rin unit with 3-dimethylallyl-4-hydroxybenzoic acid.
Likewise, the substrate of the halogenase BhaA ofthe remaining biosynthetic machinery does not accept
the modified substrates as efficiently as the genuine balhimycin biosynthesis is still elusive. Possible candi-
dates are tyrosine, -hydroxytyrosine in either free orintermediates.
The aminocoumarin antibiotic clorobiocin and the gly- enzyme bound form, or substrates derived from the later
stages of peptide assembly [32].copeptide antibiotic balhimycin both contain 3-chloro-
-hydroxy-tyrosyl-derived moieties, and the biosynthe- Our present study clearly showed that BhaA was un-
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able to functionally replace Clo-hal. We have cloned the hal by using a replicative expression plasmid, readily
allowed the production of the desired hybrid antibiotic.structural genes for both halogenases into the same
expression vector, which contains the constitutive pro- This approach opens improved possibilities for ge-
netic engineering of biosynthetic pathways of naturalmoter ermE*. Furthermore, the identical bhaA gene un-
der control of this promoter has been used successfully products in actinomycetes. At the same time, it allows
a rapid functional investigation of genes, as demon-for complementation of a bhaA-defective mutant [34].
However, only expression of clo-hal resulted in the for- strated by our finding that the halogenase BhaA, re-
sponsible for 3-chlorination of the -hydroxy-tyrosylmation of halogenated aminocoumarins in the present
study. moieties of the glycopeptide antibiotic balhimycin, is
unable to replace the halogenase Clo-hal of aminocou-To date, three different halogenating enzymes are
known: haloperoxidases, perhydrolases, and FADH2- marin biosynthesis. This finding also suggests that the
two enzymes have different substrate specificities.dependent halogenases. Clo-hal and BhaA shows se-
quence similarity to the recently discovered class of
Experimental ProceduresFADH2-dependent halogenases, which in contrast to
haloperoxidases and perhydrolases show substrate
Bacterial Strains, Plasmids, and Culture Conditionsspecificity and regioselectivity. The mechanism of halo-
Streptomyces coelicolor M512 (redD actII-ORF4 SCP1 SCP2)
genation catalyzed by FADH2-dependent halogenases [42] was kindly provided by E. Takano (Tu¨bingen, Germany) and was
is not yet completely understood. It has been speculated originally obtained from Janet White (Norwich, UK). S. spheroides
NCIMB 11891 [16] was obtained from E. Cundliffe (Leicester, UK).that the reaction may proceed via an epoxide intermedi-
The clo-hal mutant of S. roseochromogenes was described pre-ate. In vitro, these enzymes require the presence of
viously [19]. The strains were cultured as described in the citedan unspecific flavin reductase generating FADH2 [33].
references. Escherichia coli XL1 Blue MRF (Stratagene, Heidelberg,Recently, the cocrystallization of tryptophan 7-halo-
Germany) was used for cloning experiments and was grown as
genase with tryptophan and FAD was described, repre- described [43]. The REDIRECT technology kit for PCR targeting
senting an important step toward understanding the re- [24] was obtained from Plant Bioscience Limited (Norwich, UK).
Kanamycin (15 g/ml in liquid medium and 50g/ml in solid mediumaction mechanism of such enzymes [40].
for Streptomyces; 50 g/ml for E. coli), chloramphenicol (25–50Therefore, the inability of BhaA to functionally replace
g/ml), apramycin (50 g/ml), carbenicillin (50–100 g/ml), and thi-Clo-hal is unlikely to result from the specificity of the
ostrepton (15 g/ml in liquid medium and 50 g/ml in solid medium)flavin reductase. Rather, our results suggest that the
were used for selection of recombinant strains. Before transforma-
genuine substrates for the halogenation reactions cata- tion of S. coelicolor and S. roseochromogenes strains, the recombi-
lyzed by BhaA and Clo-hal are different. This is in accor- nant plasmids and cosmids were amplified in E. coli ET12567 to
avoid methyl-sensing restriction [44]. E. coli-Streptomyces shuttledance with recent evidence showing that in balhimycin
vector pUWL201 was kindly provided by A. Bechthold (Freiburg,biosynthesis halogenation apparently takes place dur-
Germany) and was originally obtained from W. Piepersberg (Wup-ing the biosynthesis of the oligopeptide backbone [41].
pertal, Germany). Cosmid 10-9C contains the novobiocin biosyn-
thetic gene cluster in the SuperCos I vector [16]. Plasmid pTLO5,
derived from pUWL201 and containing the novO gene, was de-
Significance scribed previously [19].
Metabolic engineering of biosynthetic pathways for Construction of Plasmids pAE-ha7, pAE-B3, and pUG019
pAE-ha7antibiotics, namely, the modification of specific bio-
clo-hal was amplified by PCR by using cosmid D1A8 as template andchemical reactions or the introduction of new ones
the primer pair Pclo-hal/BamHI (5-GGTCGCGGATCCCAGAAAC-3)by using recombinant DNA technology, represents a
and Pclo-hal/XbaI (5-GCCTTCGGTCTAGAAGTCC-3); underlineduseful way of creating novel drugs, especially if the
letters represent mutations inserted in comparison to the original
introduction of structural modifications by chemical sequence to give the desired restriction sites BamHI and XbaI, re-
synthesis is difficult due to the complex structure of spectively. After restriction, the fragment containing the clo-hal gene
and its natural ribosome binding site (GGAGG) was ligated into thethe respective compound. In this study, we generated
same sites of the replicative vector pUWL201, downstream of thea novobiocin analog bearing a chlorine atom instead
constitutive ermE* promoter, to give pAE-ha7 [19].of a methyl group at C-8 of the aminocoumarin core.
pAE-B3Attempts to produce this substance in the natural no-
A 1.6 kb BamHI-XbaI fragment of pSETbhaA [34], containing the
vobiocin producer Streptomyces spheroides were un- bhaA gene and its natural ribosome binding site (AGAGG), was
successful, due to the difficulties in the genetic manip- ligated into the same sites of the replicative vector pUWL201, down-
stream of the constitutive ermE* promoter, to give pAE-B3.ulation of this strain. Therefore, we modified the
pUG019cosmid containing the novobiocin biosynthetic gene
pUG019, containing an apramycin resistance cassette and flankedcluster by introducing the integrase gene, int, and the
by XbaI and SpeI recognition sites, was generated by PCR amplifica-attachment site, attP, of phageφC31, via -Red-medi-
tion of two fragments from pIJ773 (REDIRECT technology kit [24]).
ated recombination. Heterologous expression of this The first fragment of about 100 bp was amplified with primers
cosmid in S. coelicolor M512 resulted in the production FRT_P01f (5-CTGCAGGAATTCGATATTCCGGGGATCTCTAGATCT-
3; the EcoRI and XbaI restriction sites are underlined) and FRT_P01rof novobiocin in good yield, providing a novobiocin
(5-TGGCGGGGATATCGAAGTTCC-3; the EcoRV restriction site isproducer strain that is highly amenable for genetic
underlined). After digestion with EcoRI and EcoRV, this fragmentmanipulation. Inactivation of the methyltransferase
was ligated into the same sites of pBlueskript SK() (Stratagene,novO could be rapidly achieved in the cosmid by
Heidelberg, Germany) to give pUG017. The second fragment of
-Red-mediated recombination in Escherichia coli. about 1 kb containing the apramycin resistance gene aac(3)IV was
Subsequent integration of the novO cosmid into the amplified with primers apra_P03f (5-GGGGATGATATCTTTATCAC
CACCGACTATTTG-3; the EcoRV restriction site is underlined) andS. coelicolor genome, followed by expression of clo-
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apra_P02r (5-TCGATAAGCTTGATGACTAGTCTGGAGCTGGAGCTG sites. The cassette for replacement of novO was generated by PCR
with the primer pair P1-NovO (5-AGATCAGCTCACTGACCCAACCTTCGA-3; the HindIII and the SpeI restriction sites are underlined).
After digestion with EcoRV and HindIII, this fragment was ligated ACGAGGGGCATCGAGATGATTCCGGGGATCTCTAGATC-3) and
P2-NovO (5CGGGTCCAGGCGCTCTGTTCGGGACAATTCCGCCGCinto the same sites of pUG017 to give pUG019.
TCAACTAGTCTGGAGCTGCTTC-3). Underlined letters represent
39 nt homologous extensions to the DNA regions immediately up-DNA Isolation, Manipulation, and Cloning
stream and downstream of novO, respectively, including the puta-Standard procedures for DNA isolation and manipulation were per-
tive start and stop codons of novO; the XbaI and SpeI restrictionformed as described by Sambrook et al. [43] and Kieser et al. [22].
sites are presented in bold letters. The PCR reaction was carriedIsolation of DNA fragments from agarose gel and purification of PCR
out in 50 l volume with 100 ng template (pUG019 digested withproducts were carried out with the NucleoSpin 2 in 1 Extract Kit
EcoRI, HindIII, and DraI), 0.2 mM dNTPs, 50 pmol of each primer,(Macherey-Nagel, Du¨ren, Germany). Isolation of cosmids and plas-
and 5% v/v DMSO, according to the manufacturer’s instructionsmids from E. coli was carried out with ion-exchange columns
(Expand High Fidelity Polymerase, Roche Molecular Biochemicals).(Nucleobond AX kits, Macherey-Nagel, Du¨ren, Germany) according
PCR conditions were as follows: denaturation at 94	C for 2 min,to the manufacturer’s protocol. Isolation of plasmid DNA from Strep-
then 10 cycles with denaturation at 94	C for 45 s; annealing at 45	Ctomyces strains was carried out by alkaline lysis and potassium
for 45 s and extension at 72	C for 90 s, then 15 cycles with annealingacetate precipitation, procedure D [22]. If required, the plasmid DNA
at 48	C; and a last elongation step at 72	C for 5 min.isolated from Streptomyces was amplified in E. coli XL1 Blue MRF
After passing through the nonmethylating E. coli ET12567, cosmidbefore restriction analysis.
DNA was digested with XbaI and SpeI and ligated overnight at 4	C.Genomic DNA was isolated from S. coelicolor strains by using
CaCl2-competent E. coli XL1 Blue MRF cells were transformed withthe Kirby mix procedure [22]. Southern blot analysis was performed
100 ng DNA. Apramycin-sensitive, kanamycin-resistant clones wereon Hybond-N nylon membrane (Amersham Biosciences, Freiburg,
analyzed by using restriction enzymes and gel electrophoresis. TheGermany) with a digoxigenin-labeled probe by using the DIG high
generated novO cosmid nov-AE8, carrying the kanamycin resis-prime DNA labeling and detection starter kit II (Roche Applied Sci-
tance gene neo, was then introduced into S. coelicolor M512 byences, Mannheim, Germany).
PEG-mediated protoplast transformation [22]. Kanamycin-resistant
clones were checked for specific genomic integration of cosmidHeterologous Expression of the Novobiocin
nov-AE8 into the φC31 attachment site by Southern blot analysis.Biosynthetic Gene Cluster
In the SuperCos I backbone of cosmid 10-9C, containing the com-
plete novobiocin biosynthetic gene cluster, the ampicillin resistance Transformation with Plasmid pTLO5, pAE-ha7, pAE-B3,
gene bla was replaced by -Red-mediated recombination with a or pUWL201
cassette containing the integrase gene, int, and attachment site, Introduction of plasmids pTLO5, pAE-ha7, pAE-B3, or pUWL201
attP, of phage φC31, as well as a tetracycline resistance gene, tet. into the novO mutant (strain S. coelicolor [nov-AE8]), or into the
Construction of pIJ787, Containing the Integrase Cassette clo-hal mutant of S. roseochromogenes, was carried out by poly-
The tetracycline resistance gene (tet) from pBR328 was amplified ethylene glycol-mediated protoplast transformation [19, 22].
with primers pIJ782forw (5-CTATGATCGACTGATGTCATCAGCG
GTGGAGTGCAATGTCATGAAATCTAACAATGCGC-3) and pIJ782-
Production and Analysis of Secondary Metabolites
rev (5-GAACTTCATGAGCTCAGCCAATCGACTGGCGAGCGGCAT
Integration mutants, transformants, and the wild-type strain of
CTCAGGTCGAGGTGGCCCGG-3). Underlined are the beginning
S. coelicolor as well as S. spheroides were cultured at 30	C and
and the end of the coding region of the tet sequence. This fragment
assayed for novobiocin production by HPLC as described previously
was used to replace the apramycin resistance gene in pIJ773 [24]
[46]. Cultivation and analysis of secondary metabolites from S. ro-
by using -Red-mediated recombination [24, 45], generating pIJ782.
seochromogenes strains were carried out as specified in [19].
The structural gene tet was thereby placed under control of the
Negative-ion FAB mass spectra were recorded on a TSQ70 spec-
apramycin resistance promoter, resulting in slightly lower resistance
trometer (Finnigan, Bremen, Germany), using diethanolamine as ma-
levels (5 g/ml instead of 10 g/ml tetracycline). tet was then ampli-
trix. 1H NMR spectra were measured on an AMX 400 spectrometer
fied from pIJ782 with primers TetAatIIforw (5-AAAAAAAGACGTCT
(Bruker, Karlsruhe, Germany), using CD3OD as solvent. For 1H NMRTGAATGGGTTCATGTG-3) and TetAatII rev (5-AAAAAAAGACGTC
data, see Table 1.
TCAGGTCGAGGTGGCCC-3). Underlined is the AatII restriction site.
Negative-ion FAB MS data (m/z [relative intensity in %]) were as
After digestion of the PCR product with AatII, it was cloned into the
follows:
same site of pSET152. Clones with tet in the same orientation as
the integrase gene int (named pSETtet1) were selected. The 4,590 Novobiocin: 611 (8, [M-H]), 568 (7, [M-CONH]), 395 (7), 378 (6),
bp MscI-PvuI fragment of pSETtet1 was ligated into the ScaI-PvuI 281 (10), 255 (24), 209 (100);
sites (i.e., into the ampicillin resistance gene, bla) of SuperCos I to Novclobiocin 117: 597 (7, [M-H]), 380 (4), 314 (6), 283 (10), 255
give pIJ787. (13), 209 (100);
Replacement of the Ampicillin Resistance Gene, bla, Novclobiocin 114: 633 (5, [M-H], 37Cl), 632 (5, [M-H], 13C), 631
in the SuperCos I Backbone by the Integrase Cassette (15, [M-H], 35Cl), 588 (5, [M-CONH]), 554 (4, [M-CH2ONCl]), 380
The DraI-BsaI-fragment of pIJ787 containing the integrase cassette (7), 255 (46), 209 (100);
and flanked by about 100 bp bla sequence on one side and about Novclobiocin 119: 633 (10, [M-H], 37Cl), 632 (11, [M-H], 13C), 631
300 bp bla sequence on the other side was used to replace the bla (32, [M-H], 35Cl), 588 (12, [M-CONH]), 554 (6, [M-CH2ONCl]),
gene in the SuperCos I backbone of cosmid 10-9C, which contains 400 (25), 255 (68), 209 (100).
the entire novobiocin biosynthetic gene cluster. The resulting cos-
mid was termed nov-BG1.
BioassayHeterologous Expression of the Intact Novobiocin Cluster
Antibacterial activity of authentic novobiocin (Fluka) and novclobio-Cosmid nov-BG1, still carrying the kanamycin resistance gene neo,
cins against Bacillus subtilis ATCC 14893 was determined by a disc-was then introduced into S. coelicolor M512 via PEG-mediated pro-
diffusion assay, as described elsewhere [19].toplast transformation [22]. Kanamycin-resistant clones were checked
for specific genomic integration of the cosmid into theφC31 attach-
ment site by Southern blot analysis. Acknowledgments
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